Literature DB >> 3426245

Identity of the activator proteins for the enzymatic hydrolysis of sulfatide, ganglioside GM1, and globotriaosylceramide.

A Vogel1, W Fürst, M A Abo-Hashish, M Lee-Vaupel, E Conzelmann, K Sandhoff.   

Abstract

The activator protein for the enzymatic hydrolysis of sulfatide, ganglioside GM1, and globotriaosylceramide was purified from human kidney, brain, and urine. As far as they could be assayed, these three activities cochromatographed during all steps, indicating that they are due to the same protein. This result was corroborated by immunochemical comparison of individually purified activator preparations. In contrast, the activator for ganglioside GM2 hydrolysis could clearly be separated from the other activities. Kinetic data were determined for the interaction of the sulfatide activator with the different glycolipids and hydrolases.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3426245     DOI: 10.1016/0003-9861(87)90529-7

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  9 in total

1.  Evidence for two cDNA clones encoding human GM2-activator protein.

Authors:  S Nagarajan; H C Chen; S C Li; Y T Li; J M Lockyer
Journal:  Biochem J       Date:  1992-03-15       Impact factor: 3.857

2.  Sphingolipid activator protein 1 deficiency in metachromatic leucodystrophy with normal arylsulphatase A activity. A clinical, morphological, biochemical, and immunological study.

Authors:  W Schlote; K Harzer; H Christomanou; B C Paton; B Kustermann-Kuhn; B Schmid; J Seeger; U Beudt; I Schuster; U Langenbeck
Journal:  Eur J Pediatr       Date:  1991-06       Impact factor: 3.183

3.  Metabolism of GM1 ganglioside in cultured skin fibroblasts: anomalies in gangliosidoses, sialidoses, and sphingolipid activator protein (SAP, saposin) 1 and prosaposin deficient disorders.

Authors:  B Schmid; B C Paton; K Sandhoff; K Harzer
Journal:  Hum Genet       Date:  1992-07       Impact factor: 4.132

4.  Additional biochemical findings in a patient and fetal sibling with a genetic defect in the sphingolipid activator protein (SAP) precursor, prosaposin. Evidence for a deficiency in SAP-1 and for a normal lysosomal neuraminidase.

Authors:  B C Paton; B Schmid; B Kustermann-Kuhn; A Poulos; K Harzer
Journal:  Biochem J       Date:  1992-07-15       Impact factor: 3.857

5.  Methionine oxidation within the cerebroside-sulfate activator protein (CSAct or Saposin B).

Authors:  J P Whitelegge; B Penn; T To; J Johnson; A Waring; M Sherman; R L Stevens; C B Fluharty; K F Faull; A L Fluharty
Journal:  Protein Sci       Date:  2000-09       Impact factor: 6.725

Review 6.  Sphingolipid activator protein deficiency in a 16-week-old atypical Gaucher disease patient and his fetal sibling: biochemical signs of combined sphingolipidoses.

Authors:  K Harzer; B C Paton; A Poulos; B Kustermann-Kuhn; W Roggendorf; T Grisar; M Popp
Journal:  Eur J Pediatr       Date:  1989-10       Impact factor: 3.183

7.  Prosaposin deficiency: further characterization of the sphingolipid activator protein-deficient sibs. Multiple glycolipid elevations (including lactosylceramidosis), partial enzyme deficiencies and ultrastructure of the skin in this generalized sphingolipid storage disease.

Authors:  V Bradová; F Smíd; B Ulrich-Bott; W Roggendorf; B C Paton; K Harzer
Journal:  Hum Genet       Date:  1993-09       Impact factor: 4.132

Review 8.  My journey into the world of sphingolipids and sphingolipidoses.

Authors:  Konrad Sandhoff
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2012       Impact factor: 3.493

9.  A saposin deficiency model in Drosophila: Lysosomal storage, progressive neurodegeneration and sensory physiological decline.

Authors:  Samantha J Hindle; Sarita Hebbar; Dominik Schwudke; Christopher J H Elliott; Sean T Sweeney
Journal:  Neurobiol Dis       Date:  2016-11-30       Impact factor: 5.996

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.